In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome (PCOS and ivf)

Bulent Haydardedeoglu

Status: Terminated

Conditions: PCOS GnRH Antagonist and GnRH Agonist IVF/ICSI Cycles

Treatments: Other: To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle; Other: GnRH Antagonist

Study type: Interventional

Funder types: Other

Identifiers

NCT01354275

KA04/104 (Other Identifier)

BH532008

Details and patient eligibility

About

Outcomes of IVF/ICSI cycles of women with PCOS undergoing Gonadotropin Releasing Hormone (GnRH) agonist and GnRH Antagonist fixed protocol.

Full description

Women with PCOS undergoing IVF/ICSI cycles will be evaluated by two different protocols. One arm of the study includes oral contraceptive plus GnRH agonist protocol with 150 IU FSH (standard dose) and second arm includes oral contraceptive plus GnRH Antagonist with 150 IU FSH dose and fixed 6th day starting of GnRH Antagonist.

Enrollment: 300 patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• PCOS women undergoing ICSI cycles
• All women will be administered 150 IU rec FSH

Exclusion criteria

• Women having other endocrinopathies
• women older than 35
• third IVF/ICSI cycles
• previous and current use of metformin

Trial design

300 participants in 2 patient groups

GnRH Agonist

Active Comparator group

Description:

oral contraceptive pill and GnRH Agonist IVF/ICSI cycle

Treatment:

Other: To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle

GnRH Agonist Arm

Active Comparator group

Description:

Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach \>17 mm hCG will be administered.

Treatment:

Other: GnRH Antagonist

Other: To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle